7,596 results match your criteria Mycosis Fungoides


Clinical characteristics and long-term outcomes of 97 Korean patients with mycosis fungoides.

Int J Dermatol 2021 May 15. Epub 2021 May 15.

Department of Dermatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Background: Mycosis fungoides (MF) shows racial and regional differences in terms of clinical features. The availability of therapeutic options as well as drugs differs from one country to another. There are only limited data on the clinical characteristics and treatment experience of MF from South Korea. Read More

View Article and Full-Text PDF

Folliculotropic Mycosis Fungoides With Flexural Eruptive Cysts and Comedones in a 14-Year-Old Boy.

Am J Dermatopathol 2021 May 11. Epub 2021 May 11.

Dermatology Department, Hospital Universitario y Politécnico la Fe, Valencia, Spain; Pathology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain; and Departments of Pathology, and Medicine, School of Medicine, Universitat de València, Valencia, Spain.

View Article and Full-Text PDF

How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.

Br J Haematol 2021 May 14. Epub 2021 May 14.

Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.

T-cell lymphomas (TCLs) constitute a rare subset of non-Hodgkin lymphomas, with mycosis fungoides/Sézary syndrome (MF/SS) being the most common subtype of cutaneous TCLs (CTCLs). Considered an incurable but treatable disease, MF/SS management presents several challenges including diagnostic delays, debilitating effect on patients' quality of life, need for several lines of therapies, multidisciplinary care and cumulative drug toxicities limiting duration of use. The present review intends to provide an overview of the recent advances in our understanding of the biology of CTCL and how these are being leveraged to provide additional treatment options for management of advanced and recurrent disease. Read More

View Article and Full-Text PDF

[Ⅲ.Current Treatment of Mycosis Fungoides].

Authors:
Mikio Ohtsuka

Gan To Kagaku Ryoho 2021 Apr;48(4):508-512

Dept. of Dermatology, Fukushima Medical University School of Medicine.

View Article and Full-Text PDF

Biophysical and ultrasonographic changes in early patch/plaque stage of mycosis fungoides, compared with uninvolved skin.

Skin Res Technol 2021 May 11. Epub 2021 May 11.

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.

Background: The goal of this study was evaluation of the skin biophysical properties in early patch/plaque stage of mycosis fungoides (MF) and its comparison with uninvolved skin in order to gain a better understanding of the pathogenesis of diseases.

Materials And Methods: The stratum corneum hydration, transepidermal water loss (TEWL), surface friction, pH, sebum, melanin, erythema, temperature, elasticity parameters (R0, R2, R5), thickness, and echo density of epidermis and dermis were measured on lesions of 21 patients and compared with controls (average measures of uninvolved perilesional and symmetrical skins) by paired sample t test.

Results: Stratum corneum hydration (P < 0. Read More

View Article and Full-Text PDF

Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells.

Front Immunol 2021 21;12:666935. Epub 2021 Apr 21.

Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma. While initially restricted to the skin, malignant cells can appear in blood, bone marrow and secondary lymphoid organs in later disease stages. However, only little is known about phenotypic and functional properties of malignant T cells in relationship to tissue environments over the course of disease progression. Read More

View Article and Full-Text PDF

The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas.

Support Care Cancer 2021 May 7. Epub 2021 May 7.

Division of Dermatology, City of Hope, Duarte, USA.

Purpose: Cutaneous lymphomas (CLs) are a group of rare, potentially disfiguring and disabling cancers that can have a significant impact on quality of life (QoL). While previous studies have shown that mycosis fungoides (MF) and Sézary syndrome (SS) impair QoL, the effect of other types of CL on QoL has not been evaluated.

Objective: To determine the impact of disease on QoL in all CL patients and to assess how QoL between the CL sub-types varies by demographic and clinical factors. Read More

View Article and Full-Text PDF

Mycosis Fungoides with Photosensitivity Mimicking Chronic Actinic Dermatitis.

Indian Dermatol Online J 2021 Mar-Apr;12(2):337-339. Epub 2020 Sep 28.

Department of Pathology, Armed Forces Medical College, Pune, Maharashtra, India.

View Article and Full-Text PDF
September 2020

Article Topic/Title: Primary cutaneous T-cell lymphomas other than Mycosis Fungoides and Sezary Syndrome. Part II: Prognosis and Management.

J Am Acad Dermatol 2021 May 1. Epub 2021 May 1.

Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Primary cutaneous T-cell lymphomas (CTCLs) other than Mycosis Fungoides (MF) and Sézary syndrome (SS) encompass a heterogenous group of non-Hodgkin lymphomas with variable clinical course, prognoses, and management. With morphologic and histologic overlap among the CTCL subtypes and other T-cell lymphomas with cutaneous manifestations, thorough evaluation with clinicopathologic correlation and exclusion of systemic involvement are essential prior to initiating therapy. Staging and treatment recommendations vary depending on the subtype, clinical behavior, and treatment response. Read More

View Article and Full-Text PDF

Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers.

J Dtsch Dermatol Ges 2021 May 4. Epub 2021 May 4.

Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Medical Centre, University Hospital of Ruhr-University Bochum, Minden, Germany.

View Article and Full-Text PDF

Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.

BMC Cancer 2021 May 3;21(1):492. Epub 2021 May 3.

Department of Dermatology, University of Arkansas for Medical Sciences, 4301 West Markham St, #576, Little Rock, AR, 72205, USA.

Background: Mycosis fungoides (MF) is a primary cutaneous T-cell lymphoma (CTCL) that transforms from mature, skin-homing T cells and progresses during the early stages in the skin. The role of the skin microenvironment in MF development is unclear, but recent findings in a variety of cancers have highlighted the role of stromal fibroblasts in promoting or inhibiting tumorigenesis. Stromal fibroblasts are an important part of the cutaneous tumor microenvironment (TME) in MF. Read More

View Article and Full-Text PDF

Primary cutaneous T-cell lymphomas other than Mycosis Fungoides and Sezary Syndrome - Part I: Clinical and histologic features and diagnosis.

J Am Acad Dermatol 2021 Apr 30. Epub 2021 Apr 30.

Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Primary cutaneous T-cell lymphomas (CTCLs) are defined as lymphomas with a T-cell phenotype that present in the skin without evidence of systemic or extracutaneous disease at initial presentation. CTCLs other than Mycosis Fungoides (MF) and Sézary syndrome (SS) account for approximately one-third of CTCLs and encompass a heterogenous group of non-Hodgkin lymphomas ranging from indolent lymphoproliferative disorders to aggressive malignancies with a poor prognosis. The spectrum of CTCLs continues to broaden as new provisional entities are classified. Read More

View Article and Full-Text PDF

Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: Three Case Reports.

Adv Ther 2021 Apr 30. Epub 2021 Apr 30.

2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece.

Introduction: Chlormethine gel is a skin-directed therapy recommended for patients with early-stage mycosis fungoides (MF) cutaneous T cell lymphoma.

Methods: Herein, we present three cases of patients with stage IB-IIB MF who were treated with chlormethine gel and concomitant therapies.

Results: All patients responded well to treatment with chlormethine gel; complete responses were observed with improvements in Modified Severity-Weighted Assessment Tool scores and severity of lesions; one patient reported an improvement in quality of life. Read More

View Article and Full-Text PDF

Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy.

Cancers (Basel) 2021 Apr 16;13(8). Epub 2021 Apr 16.

Molecular Biology Department, Universidad de Cantabria-Instituto de Investigación Marqués de Valdecilla, IDIVAL, 39011 Santander, Spain.

Primary cutaneous T-cell lymphomas (CTCLs) constitute a heterogeneous group of diseases that affect the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) account for the majority of these lesions and have recently been the focus of extensive translational research. This review describes and discusses the main pathobiological manifestations of MF/SS, the molecular and clinical features currently used for diagnosis and staging, and the different therapies already approved or under development. Read More

View Article and Full-Text PDF

Erythroderma: psoriasis or lymphoma? A diagnostic challenge and therapeutic pitfall.

Ital J Dermatol Venerol 2021 Apr 29. Epub 2021 Apr 29.

Division of Dermatology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Background: Psoriasis and lymphoma risk is widely debated, but few is known about misdiagnosis risk between erythrodermic psoriasis and lymphoma . In fact erythroderma might represent a clinical presentation of psoriasis, cutaneous T cell lymphomas and skin dissemination of systemic lymphomas.

Methods: All patients referred to psoriasis outpatient service with a diagnosis of erythrodermic psoriasis were re-examined. Read More

View Article and Full-Text PDF

Papular mycosis fungoides localized on the chest with a favorable prognosis.

J Dermatol 2021 Apr 23. Epub 2021 Apr 23.

Department of Dermatology, Shizuoka General Hospital, Shizuoka, Japan.

View Article and Full-Text PDF

Novel therapeutic approaches for cutaneous T cell lymphomas.

Expert Rev Clin Immunol 2021 May 11:1-13. Epub 2021 May 11.

2nd Department of Dermatology and Venereal Diseases, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

: Cutaneous T-cell lymphoma (CTCL) is a rare non-Hodgkin's lymphoma, characterized by malignant T cells infiltrating the skin. CTCL exhibits vast heterogeneity which complicates diagnosis and therapeutic strategies. Current CTCL treatment includes skin-directed therapies (such as topical corticosteroid, topical mechlorethamine, topical bexarotene, ultraviolet phototherapy and localized radiotherapy), total skin electron beam therapy and systemic therapies. Read More

View Article and Full-Text PDF

Granulomas in Dermatopathology: Principal Diagnoses - Part 1.

Actas Dermosifiliogr 2021 Apr 19. Epub 2021 Apr 19.

Servicio de Anatomía Patológica, Hospital Universitario El Bierzo, Ponferrada, España; Servicio de Anatomía Patológica, Hospital de La Reina, Ponferrada, España; Unidad de Investigación. Instituto de Investigación Biomédica de A Coruña (INIBIC). Universidad de A Coruña, A Coruña, España. Electronic address:

This series of 2 articles on dermatopathologic diagnoses reviews conditions in which granulomas form. Part 1 clarifies concepts, discusses the presentation of different types of granulomas and giant cells, and considers a large variety of noninfectious diseases. Some granulomatous diseases have a metabolic origin, as in necrobiosis lipoidica. Read More

View Article and Full-Text PDF

Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.

JAMA Dermatol 2021 Apr 21. Epub 2021 Apr 21.

Department of Dermatology, Stanford University School of Medicine, Palo Alto, California.

Importance: Mogamulizumab is a monoclonal antibody against CCR4 approved for treatment for mycosis fungoides (MF) and Sézary syndrome (SS). Mogamulizumab-associated rash (MAR) is difficult to differentiate from cutaneous MF or SS, which can lead to unnecessary discontinuation of drug use because of concern for severe drug reaction or incorrect presumption of disease relapse or progression in the skin.

Objective: To examine the most common clinical presentations of MAR in patients with MF or SS and the diagnostic and management challenges. Read More

View Article and Full-Text PDF

Phototherapy as a treatment of early-stage mycosis fungoides and predictive factors for disease recurrence: A 17-year retrospective study.

Indian J Dermatol Venereol Leprol 2021 Apr 12:1-7. Epub 2021 Apr 12.

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. Narrowband ultraviolet B and psoralen and ultraviolet A are effective treatment options, but studies of their treatment efficacy and disease relapse remain limited.

Objectives: This study aimed (1) to determine the efficacy of narrowband ultraviolet B and psoralen and ultraviolet A as a treatment for early-stage mycosis fungoides and explore the predictive factors for complete remission and (2) to determine the relapse rate and analyze their predictive factors, including the utility of maintenance therapy. Read More

View Article and Full-Text PDF

Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma.

J Invest Dermatol 2021 Apr 20. Epub 2021 Apr 20.

LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. Electronic address:

Staphylococcal enterotoxins are believed to fuel disease activity in cutaneous T-cell lymphoma. Recent data support this by showing that antibiotics inhibit malignant T cells in skin lesions in mycosis fungoides and Sézary syndrome, the most common forms of cutaneous T-cell lymphoma. Yet, it remains incompletely characterized how staphylococcal enterotoxins fuel disease activity. Read More

View Article and Full-Text PDF

Primary cutaneous T-cell lymphomas in childhood and adolescence.

J Dtsch Dermatol Ges 2021 04;19(4):563-581

Department of Dermatology and Allergology, Paracelsus Medical University Salzburg, Salzburg, Austria.

Primary cutaneous lymphomas are extranodal non-Hodgkin lymphomas of T- or B- cell origin, that predominantly affect older patients but have been reported in all age groups and as early as in the first years of life. Diagnosis of cutaneous lymphomas is challenging and requires high clinical suspicion and close collaboration between dermatologists, pediatric oncologists and pathologists. Skin involvement of non-Hodgkin lymphomas in children or adolescents can either be primary cutaneous or secondary due to an underlying nodal lymphoma. Read More

View Article and Full-Text PDF

Primär kutane T-Zell-Lymphome im Kindes- und Jugendalter.

J Dtsch Dermatol Ges 2021 Apr;19(4):563-583

Klinik für Dermatologie und Allergologie, Paracelsus Medizinische Privatuniversität Salzburg, Österreich.

Primär kutane Lymphome sind extranodale T- oder B-Zell-Non-Hodgkin-Lymphome, die vorwiegend ältere Patienten betreffen, aber in allen Altersgruppen einschließlich der ersten Lebensjahre auftreten können. Die Diagnose kutaner Lymphome ist eine Herausforderung und erfordert einen hohen klinischen Verdacht sowie enge Zusammenarbeit zwischen Dermatologen, pädiatrischen Onkologen und Pathologen. Generell müssen primär kutane Lymphome von sekundär kutanen Lymphomen, welche meist von nodalen oder extranodalen Lymphomen ausgehen, unterschieden werden. Read More

View Article and Full-Text PDF

Successful treatment of palmoplantar dyshidrotic lesions of mycosis fungoides with conventional and daylight photodynamic therapy.

J Dtsch Dermatol Ges 2021 Apr 16. Epub 2021 Apr 16.

Department of Dermatology, Alicante University General Hospital and Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.

View Article and Full-Text PDF

Critical concepts and management recommendations for cutaneous T-cell lymphoma: A consensus-based position paper from the Italian Group of Cutaneous Lymphoma.

Hematol Oncol 2020 Dec 13. Epub 2020 Dec 13.

Dermatology Department, University of Firenze, Firenze, Italy.

In this paper, we present a review of critical concepts, and produce recommendations on management issues in cutaneous T-cell lymphomas (CTCLs) of adults. A panel of nine experts was selected for their expertise in research and clinical practice of CTCLs. During an initial meeting, the areas of major concern in the management of CTCLs were selected by generating and rank-ordering clinical key questions using the criterion of clinical relevance, through group discussion. Read More

View Article and Full-Text PDF
December 2020

Antibiotics and Imiquimod for Cutaneous T-Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure.

Oncologist 2021 Apr 14. Epub 2021 Apr 14.

Department of Dermatology, James J. Peters Veterans Affairs Medical Center, Bronx, New York, USA.

Lessons Learned: Staphylococcus aureus infection in cutaneous T-cell lymphoma (CTCL) is thought to contribute to disease progression; thus, adjunctive treatment with antibiotics warrants further investigation. This trial of antibiotic therapy followed by imiquimod in early stage CTCL was not completed because of difficulties with patient accrual.

Background: Cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin lymphoma, is a heterogeneous group of malignancies of mature memory T lymphocytes. Read More

View Article and Full-Text PDF

Mycosis Fungoides: Uncommon Presentation.

Int J Appl Basic Med Res 2021 Jan-Mar;11(1):53-55. Epub 2021 Jan 26.

Centre of Excellence in Nursing Education and Research, AIIMS, Rishikesh, Uttarakhand, India.

Mycoses fungoides is a common cutaneous T cell lymphoma. Tumor and ulcerative stages are advanced lymphoma. We report a case of mycosis fungoides that presented with ulcerated plaques and nodules over the body and infraorbital region, he was being treated as leprosy without improvement of the lesions. Read More

View Article and Full-Text PDF
January 2021

Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for molecular-specific treatment.

Int J Dermatol 2021 Apr 9. Epub 2021 Apr 9.

Instituto de Biología, Universidad de Antioquia, Medellin, Colombia.

Cutaneous T-cell lymphomas (CTCL) result from the infiltration and proliferation of a population of T cells in the skin, inducing changes in the activity of both T cells and surrounding skin cells. In the CTCL microenvironment, cell interactions mediated by cell signaling pathways are altered. Defining changes in cell signaling enables to understand T-cell deregulations in the CTCL microenvironment and thus the progression of the disease. Read More

View Article and Full-Text PDF

[Management of mycosis fungoide : focus on brentuximab vedotin].

Rev Med Liege 2021 Apr;76(4):224-231

) Service de Dermatologie, CHU Liège, Belgique.

Recently, brentuximab vedotin (BV) (Adcetris®) obtained the reimbursement in Belgium for the treatment of the primary cutaneous NKT-cell lymphomas mycosis fungoides (MF), large cell anaplastic lymphoma and lymphomatoid papulosis type A. BV is a monoclonal antibody directed against the CD30 expressed on tumoral T cells. The inhibition of this pathway releases the process of apoptosis leading to the cell death of the tumoral cells. Read More

View Article and Full-Text PDF